Evidence map›Paper›PMID 26573612›Full record

ArticleBMC genomics2015

Functional analysis and transcriptional output of the Göttingen minipig genome.

Tobias Heckel, Roland Schmucki, Marco Berrera, Stephan Ringshandl, Laura Badi, Guido Steiner, Morgane Ravon, Erich Küng, Bernd Kuhn, Nicole A Kratochwil and 12 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. From the Cover: The Minipig is a Suitable Non-Rodent Model in the Safety Assessment of Single Stranded Oligonucleotides.Toxicological sciences : an official journal of the Society of Toxicology · 2017
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 2 countries.

Tobias HeckelRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. tobias.heckel@roche.com.
Roland SchmuckiRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. roland.schmucki@roche.com.
Marco BerreraRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. marco.berrera@roche.com.
Stephan RingshandlRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. stephan.ringshandl@Synmikro.Uni-Marburg.de.
Laura BadiRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. laura.badi@roche.com.
Guido SteinerRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. guido.steiner@roche.com.
Morgane RavonRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. morgane.ravon.mr1@roche.com.
Erich KüngRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. erich.kueng@roche.com.
Bernd KuhnRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. bernd.kuhn@roche.com.
Nicole A KratochwilRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. nicole_a.kratochwil@roche.com.
Georg SchmittRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. georg.schmitt@roche.com.
Anna KiialainenRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. anna.kiialainen@roche.com.
Corinne NowaczykRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. corinne.nowaczyk@roche.com.
Hamina DaffRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. hamina.daff@roche.com.
Azinwi Phina KhanRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. AzinwiPhina.Khan@uk-essen.de.
Isaac LekoloolInternational Livestock Research Institute (ILRI), PO Box 30709, Nairobi, 00100, Kenya. lekolool@kws.go.ke.
Roger PelleInternational Livestock Research Institute (ILRI), PO Box 30709, Nairobi, 00100, Kenya. r.pelle@cgiar.org.
Edward OkothInternational Livestock Research Institute (ILRI), PO Box 30709, Nairobi, 00100, Kenya. e.okoth@cgiar.org.
Richard BishopInternational Livestock Research Institute (ILRI), PO Box 30709, Nairobi, 00100, Kenya. r.bishop@cgiar.org.
Claudia DaubenbergerSwiss Tropical and Public Health Institute (Swiss TPH), Socinstr. 57, CH 4002, Basel, Switzerland. claudia.daubenberger@unibas.ch.
Martin EbelingRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. martin.ebeling@roche.com.
Ulrich CertaRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. ulrich.certa@roche.com.
Roche (Switzerland) · CHInternational Livestock Research Institute · KESwiss Tropical and Public Health Institute · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the past decade the Göttingen minipig has gained increasing recognition as animal model in pharmaceutical and safety research because it recapitulates many aspects of human physiology and metabolism. Genome-based comparison of drug targets together with quantitative tissue expression analysis allows rational prediction of pharmacology and cross-reactivity of human drugs in animal models thereby improving drug attrition which is an important challenge in the process of drug development.

resultsHere we present a new chromosome level based version of the Göttingen minipig genome together with a comparative transcriptional analysis of tissues with pharmaceutical relevance as basis for translational research. We relied on mapping and assembly of WGS (whole-genome-shotgun sequencing) derived reads to the reference genome of the Duroc pig and predict 19,228 human orthologous protein-coding genes. Genome-based prediction of the sequence of human drug targets enables the prediction of drug cross-reactivity based on conservation of binding sites. We further support the finding that the genome of Sus scrofa contains about ten-times less pseudogenized genes compared to other vertebrates. Among the functional human orthologs of these minipig pseudogenes we found HEPN1, a putative tumor suppressor gene. The genomes of Sus scrofa, the Tibetan boar, the African Bushpig, and the Warthog show sequence conservation of all inactivating HEPN1 mutations suggesting disruption before the evolutionary split of these pig species. We identify 133 Sus scrofa specific, conserved long non-coding RNAs (lncRNAs) in the minipig genome and show that these transcripts are highly conserved in the African pigs and the Tibetan boar suggesting functional significance. Using a new minipig specific microarray we show high conservation of gene expression signatures in 13 tissues with biomedical relevance between humans and adult minipigs. We underline this relationship for minipig and human liver where we could demonstrate similar expression levels for most phase I drug-metabolizing enzymes. Higher expression levels and metabolic activities were found for FMO1, AKR/CRs and for phase II drug metabolizing enzymes in minipig as compared to human. The variability of gene expression in equivalent human and minipig tissues is considerably higher in minipig organs, which is important for study design in case a human target belongs to this variable category in the minipig. The first analysis of gene expression in multiple tissues during development from young to adult shows that the majority of transcriptional programs are concluded four weeks after birth. This finding is in line with the advanced state of human postnatal organ development at comparative age categories and further supports the minipig as model for pediatric drug safety studies.

conclusionsGenome based assessment of sequence conservation combined with gene expression data in several tissues improves the translational value of the minipig for human drug development. The genome and gene expression data presented here are important resources for researchers using the minipig as model for biomedical research or commercial breeding. Potential impact of our data for comparative genomics, translational research, and experimental medicine are discussed.

Indexed as

GenomeAgingAnimalsChromosomesGene ExpressionGene Expression ProfilingHumansLiverPharmaceutical PreparationsPseudogenesSpecies SpecificitySwineSwine, MiniatureTranscription, GeneticPharmaceutical Preparations

Identifiers

PMID26573612
PMCPMC4647470
OpenAlexW2206932130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.